Side-by-side · Research reference
IpamorelinvsSelank
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 1Reviewed21/57 cited
BHuman-MechanisticDraft11/40 cited
Ipamorelin
Selective GHRP · Ghrelin Mimetic
SQ · Multiple sites · 1–3×/day
Selank
Anxiolytic + Cognitive · Russian Pharma
Intranasal · 2–3×/day during stress / cognitive demand
01Mechanism of Action
Parameter
Ipamorelin
Selank
Primary target
Ghrelin receptor (GHS-R1a) on anterior pituitaryRaun 1998
Monoamine system (serotonin / GABA modulation) + immunomodulation via tuftsin domainZaderej 2014
Pathway
GHS-R1a binding → Gαq/11 → ↑intracellular Ca²⁺ → GH vesicle exocytosisRaun 1998Bowers 1991
Tuftsin-derived immune signaling + CNS monoamine modulation → reduced anxiety + improved mood / cognitionMedvedev 2007
Downstream effect
GH pulse amplification, IGF-1 elevation, recovery and lipolytic effectsBowers 2002
Anxiolytic + cognitive enhancement; immunomodulation via increased IL-6 + IFN-γMedvedev 2007Zaderej 2014
Feedback intact?
Yes — pulsatile pattern preserved; somatostatin feedback activeBowers 2002
No GABA-receptor binding; no dependence reportedMedvedev 2007
Origin
Pentapeptide H-Aib-His-D-2-Nal-D-Phe-Lys-NH₂; rationally designed for ghrelin-receptor selectivityRaun 1998
Synthetic 7-AA peptide derived from human tuftsin (immune-system tetrapeptide)Zaderej 2014
Antibody development
Not reported in short-term studies
—
02Dosage Protocols
Parameter
Ipamorelin
Selank
Standard dose
200–300 mcg per injectionRaun 1998
Anecdotal community range; clinical doses 1–3 mg IV in trials.
150–300 mcg / dose intranasalZaderej 2014
Frequency
1–3× per day
Once daily pre-sleep is most common; twice or thrice for advanced users.
2–3× per day during stress
Lower / starter dose
100 mcg per dose
75 mcg / dose
Evidence basis
Phase 1 + clinical practiceRaun 1998Sigalos 2018
Human-mechanistic + Russian clinical trialsMedvedev 2007
Duration
8–12 weeks on / 4 weeks off (anecdotal)
GHS-R desensitisation reported with continuous dosing.
10–14 day cycles, repeated as needed
Reconstitution
Bacteriostatic water; typical 2 mL per 5 mg vial
Pre-formulated nasal spray (commercial); research vial: bacteriostatic water
Timing
Pre-sleep + fasted preferred; 30 min away from food
Morning + early afternoon preferred
Half-life
~2 hoursRaun 1998
Longer than GHRP-6 (15 min); shorter than CJC-1295-DAC (~8 days).
Short (minutes plasma); CNS effect lasts ~3 hr
04Side Effects & Safety
Parameter
Ipamorelin
Selank
Hunger
Mild appetite increase via ghrelin-receptor crosstalk
—
Injection site reaction
Mild irritation possible
—
GH excess (overdose)
Joint pain, edema, insulin resistance
—
IGF-1 elevation
Dose-dependent; monitor with chronic high-dose use
—
Cancer risk
Theoretical via GH/IGF-1 axis; contraindicated in active malignancy
—
Pregnancy / OB
Avoid
Avoid — insufficient data
Nasal irritation
—
Mild burning or congestion (transient)
Cognitive impairment
—
None — opposite effect (enhancement)
Allergic reaction
—
Rare hypersensitivity
Long-term safety
—
Limited Western RCT data
Absolute Contraindications
Ipamorelin
- ·Active malignancy or cancer history
- ·Pregnancy / breastfeeding
- ·Disrupted hypothalamic-pituitary axis
Selank
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to peptide
Relative Contraindications
Ipamorelin
- ·Untreated diabetes
- ·Severe insulin resistance
- ·Concurrent corticosteroid use (theoretical desensitisation)
Selank
- ·Active autoimmune disease (theoretical via immunomodulation)
05Administration Protocol
Parameter
Ipamorelin
Selank
1. Reconstitution
Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL. Roll gently. Solution should be clear.
Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.
2. Injection site
Subcutaneous, abdomen or thigh. Rotate sites. Pinch fat for shallow SQ delivery.
Intranasal — 1–3 sprays per nostril per dose. Tilt head slightly back.
3. Timing
Pre-sleep optimal — aligns with natural GH pulse. Some protocols add a morning fasted dose.
Morning + early afternoon for cognitive demand; PRN for acute anxiety.
4. Storage
Lyophilised: room temp, protected from light. Reconstituted: refrigerate 2–8 °C, use within 30 days.
Refrigerate after reconstitution; ≤30 days. Light-protected.
5. Needle
29–31G, 4–8 mm insulin syringe.
Avoid co-administration with strong sedatives or other anxiolytics initially.
06Stack Synergy
Ipamorelin
+ Tesamorelin
StrongIpamorelin (GHRP) + tesamorelin (GHRH analogue) is the textbook dual-axis GH stack. They activate two distinct pituitary receptors — the ghrelin receptor and the GHRH receptor — producing a synergistic GH pulse larger than either alone. Ipamorelin's selectivity (no cortisol/prolactin spike) makes it the ideal GHRP partner for long-term protocols.
- Ipamorelin
- 200–300 mcg SQ · pre-sleep
- Tesamorelin
- 2 mg SQ · same injection · pre-sleep
- Primary benefit
- Maximal GH pulsatility, fat loss, recovery, sleep depth
+ CJC-1295 (no DAC)
StrongCJC-1295 (no DAC) is a short-acting GHRH analogue. Combined with ipamorelin (GHRP), the pulse is amplified across both receptor systems with timing similar to native physiology. Without the DAC modification, the stack maintains sharp peaks rather than the sustained elevation seen with CJC-1295-DAC + ipamorelin.
- Ipamorelin
- 200–300 mcg SQ · pre-sleep
- CJC-1295 (no DAC)
- 100 mcg SQ · same injection
- Primary benefit
- Pulsatile GH stimulation matching physiological pattern
Selank
— no documented stacks